Accelerate Diagnostics — Investor Presentation (June 2023)
20 slides from Accelerate Diagnostics's investor presentation, Jun 13, 2023
Slide 1: Accelerate Diagnostics Investor Presentation
ACCELERATE DIAGNOSTICS INVESTOR PRESNTATION Jack Phillips President & CEO Accelerate Diagnostics, Inc May 2023
Slide 2: Confidentiality and disclaimer notice
The information contained herein has been prepared by Accelerate Diagnostics, Inc. and its affiliates (the “Company”) and is highly confidential and proprietary information and may not be disclosed by the recipient to any other person or entity without the explicit written permission of the Company.
Slide 3: Executive Summary
Accelerate created the rapid microbiology testing market: first FDA approval, strong IP, notable customers, dozens of publications, and high clinical impact. New commercial partnership with Becton Dickinson driving near-term commercial momentum with Accelerate Pheno® and Accelerate Arc™ Next generat
Slide 4: Corporate Strategic Priorities
Grow Market Share Deliver Innovation Corporate Strategic Priorities Financial Strength Driven by Great People, working as One Team, aligned by a common Culture 4
Slide 5: Target Market & Accelerate's Solutions
Target Market & Accelerate’s Solutions 5
Slide 6: Antimicrobial resistance & sepsis pose an escalating threat to healthcare
Antimicrobial resistance & sepsis pose an on-going and escalating threat to healthcare (1) Management estimate based on an accumulation of publicly available data sources (2) Management estimate based on conglomeration of publicly available sources (3) P. Sallenriek, et. al. Comparison of MicroScan
Slide 7: Accelerate's technology enables rapid & digitized microbiology
Digital microbiology Fastest possible AST results Automated workflows Direct from sample capable Accelerate’s technology enables rapid & digitized microbiology Yesterday's microbiology Manual workflows Trained staff intensive Slow time to result 7
Slide 8: Accelerate first to bring rapid digital testing to slow analog microbiology market
Accelerate first to bring rapid digital testing to slow analog microbiology market CONVENTIONAL METHODS WORKFLOW (E.G. VITEK, PHOENIX, MICROSCAN) ACCELERATE PHENO & WAVE WORKFLOW 26-53 HRS EARLIER UP TO 8% mortality reduction 2 days less ABX usage 2 days length of stay reduction $1,000–3,100 per pat
Slide 9: Large and evolving market creates risk to leaders & opportunity to disrupters
Large and evolving market creates risk to leaders & substantial opportunity to disrupters US Ex-US Total Positive Blood – Rapid AST 2.3 5.8 8.1 Positive Blood/Myco – Rapid ID 3.0 7.6 10.6 Isolates – Rapid AST 38.5 86.8 125.3 Isolates – Rapid ID 59.7 134.4 194.1 Total: 103.5 234.5 338.0 (1) Approxima
Slide 10: Accelerate Pheno System
Accelerate Pheno® System Integrated ID/AST Test + AST Test 10
Slide 11: Two available kits to meet varied customer workflows
Two available kits to meet varied customer workflows Blood Culture Systems Bactec™ Virtuo® Positive Blood Culture Gram Stain Molecular Identification Biomerieux BioFire® Roche ePLEX® Diasorin Verigene® Rapid Susceptibility Accelerate PhenoTest® BC kit AST Configuration Rapid Identification & Suscept
Slide 12: The financial benefit of running Pheno is proven
The financial benefit of running Pheno is proven Length of Stay –3.0 days1 –2.6 days2 –2.0 days3 –1.8 days4 Time to Optimal Therapy –26.4 hours4 –22.1 hours2 –17.7 hours5 –17.3 hours1 Days on Therapy (DOT) –4.7 days2 –1.5 days7 –1.0 days4 Clinical Outcomes Data Reporting by Customers $3,100/patient
Slide 13: Accelerate Arc Rapid MALDI Prep
Accelerate Arc™ Rapid MALDI Prep 13
Slide 14: Automated sample prep system creates an opportunity in the MALDI identification market
Automated sample prep system creates an opportunity in the MALDI identification market ~1 hr Enables rapid MALDI Blood Culture Systems Bactec™ Virtuo® Positive Blood Culture Gram Stain Rapid Susceptibility Accelerate Pheno AST Test Rapid Identification & Susceptibility Result Reportable to LIS 2 Ste
Slide 15: Wave Total Lab AST Solution
Wave™ Total Lab AST Solution 15
Slide 16: Wave: Advancing rapid susceptibility testing for positive blood culture and isolates
Wave: Advancing rapid susceptibility testing for positive blood culture and isolates with a decade of innovation Access to 10X more testing volume with isolated colony assays 90% less costly than Pheno Positive Blood Culture (PBC) consumable, highly profitable PBC and Isolate Assays Scalable system
Slide 17: Wave unleashes the power of proprietary holographic imaging
Wave unleashes the power of proprietary holographic imaging Wave Delivers • Faster single-cell analysis • Improved noise reduction, eliminate complexity without compromising signal • Enhanced accuracy for complex cases • Rich data stream which enables continued learning, and applications beyond micr
Slide 18: The Opportunity: Wave expands available market by 15x
The Opportunity: Wave expands available market by 15x Pheno ID/AST Segment Pheno AST Segment Wave Arc Isolates Rapid ID Isolates Rapid AST Positive Blood Culture Rapid AST PBC/Myco Rapid ID Expansion of Addressable Market with Wave: • Next generation Antimicrobial Susceptibility Testing (AST) platfo
Slide 19: Projections
Projections 19
Slide 20: Long-Term Financial Model
20 Long-Term Financial Model 1,2,3,4 Long-Term Financial Forecast ($ millions) (1) These are goals reflective of the midpoint of management assessment of the company's opportunity - this does not reflect formal financial guidance and should not be relied on as such. See “Cautionary Note Regarding Pr
Accelerate Diagnostics — Investor Presentation (June 2023) on 6ix